Potential Therapeutic Role of GLP-1 Receptor Agonists in the Management of Opioid Use Disorders: A Literature Review
Addiction and Health · 22.11.2025 · 17 · 1682
DOI: 10.34172/ahj.1682 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Addiction and Health, online erschienen am 22.11.2025. Verfasst von Skylar Bronson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, American University of the Caribbean School of Medicine, Cupecoy, Sint Maarten. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Opioid use disorder (OUD) is a global health crisis, contributing to significant public health challenges and economic loss. Although existing treatments are available, there is a critical need for novel therapeutic strategies. This review examined the potential of glucagon-like peptide-1 (GLP-1) receptor agonists, primarily used in diabetes management, as a repurposed treatment for OUD.
Methods
We explored preclinical studies that demonstrate how GLP-1 receptor agonists can modulate neurobiological pathways involved in opioid addiction, particularly dopaminergic signaling. We also reviewed initial human clinical trials examining the impact of GLP-1 receptor agonists on opioid self-administration, relapse behavior, and cravings.
Findings
Preclinical data suggest that GLP-1 receptor agonists can reduce opioid self-administration and relapse behavior in animal models. Early human clinical trials indicate promising results, showing a potential role for GLP-1 receptor agonists in reducing opioid cravings and improving treatment outcomes.
Conclusion
Although early findings are encouraging, further research is needed to confirm these results, optimize dosing regimens, and clarify the underlying mechanisms of action. Given the interplay between metabolic and neuropsychiatric factors in OUD, GLP-1 receptor agonists offer a unique therapeutic advantage. Large-scale clinical trials are essential to determine their long-term efficacy, safety, and integration into comprehensive OUD treatment plans.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Sciences, American University of the Caribbean School of Medicine, Cupecoy, Sint Maarten.
- Department of Clinical Sciences, St. George's University School of Medicine, West Indies, Grenada.
- Department of Clinical Sciences, Ross University School of Medicine, Miramar, Florida, United States.
- Department of Clinical Sciences, St. Matthews University School of Medicine, Orlando, Florida, United States.
- Department of Internal Medicine, River Oaks Treatment Center, Riverview, Florida, United States.
ORCID-Profile: Skylar Bronson, Kyla Groves, Seham Noorani, Danielle Boothe, Medha Gopal, Jonathan Quinonez
Zitieren
APA
Bronson, S., Groves, K., Noorani, S., Boothe, D., Gopal, M., & Quinonez, J. (2025). Potential Therapeutic Role of GLP-1 Receptor Agonists in the Management of Opioid Use Disorders: A Literature Review. Addiction and Health, 17, 1682. https://doi.org/10.34172/ahj.1682
Vancouver
Bronson S, Groves K, Noorani S, Boothe D, Gopal M, Quinonez J. Potential Therapeutic Role of GLP-1 Receptor Agonists in the Management of Opioid Use Disorders: A Literature Review. Addiction and Health. 2025;17:1682. doi:10.34172/ahj.1682
BibTeX
@article{Bronson2025,
author = {Bronson, Skylar and Groves, Kyla and Noorani, Seham and Boothe, Danielle and Gopal, Medha and Quinonez, Jonathan},
title = {Potential Therapeutic Role of GLP-1 Receptor Agonists in the Management of Opioid Use Disorders: A Literature Review},
journal = {Addiction and Health},
year = {2025},
volume = {17},
pages = {1682},
doi = {10.34172/ahj.1682}
}
EUVIMED